OGS and BioInvent form Therapeutic Antibodies Alliance
OGS and BioInvent form Therapeutic Antibodies Alliance Oxford, UK and Lund, Sweden, 14 March 2002 - Oxford GlycoSciences Plc (LSE: OGS, NASDAQ: OGSI) and BioInvent International AB (SAX: BINV) announced today a three year collaboration to identify, develop, manufacture and commercialise novel therapeutic antibodies, which will target antigens provided by OGS and will be produced using BioInvent's novel antibody technology platform, n-CoDeR(TM). Under the terms of this agreement, OGS will provide at least five target antigens per year, identified and validated through OGS' proteomics process.